Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

All British babies to receive Meningitis B vaccine
Injection
Meningitis B affects around 1,200 people every year.
Vaccine represents a significant breakthrough in disease prevention

An agreement has been reached between GlaxoSmithKline and the Department of Health which will mean all babies in the UK will soon be vaccinated against Meningitis B.

Starting in September, the vaccination programme is the culmination of more than 20 years of research and represents a significant breakthrough in disease prevention.

When the vaccine is launched, the UK will become the first country in the world to introduce a national Meningitis B vaccination programme.

In a statement, GlaxoSmithKline said: "GSK is delighted to have reached an agreement with the UK’s Department of Health that will enable babies in the UK to receive its meningitis B vaccine through the NHS immunisation schedule.

"We have moved rapidly to conclude negotiations since we acquired the vaccine from Novartis at the beginning of March.

"We believe the agreement we have reached offers fair value for the NHS and allows a reasonable return for GSK to ensure that we can continue to invest in creating new treatments and vaccines.

Meningitis B affects around 1,200 people, mainly babies and children, each year in the UK, with around one in every ten dying from the infection. Many of those who survive suffer terrible permanent disability such as limb loss, brain damage and epilepsy.


Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.